Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Olaparib for PALB2 or BRCA1/2 Mutated Breast Cancer
The phase II TBCRC 048 study found olaparib to be effective in metastatic breast cancer patients with germline PALB2 or somatic BRCA1/2 mutations. The overall response rate was sig
New Protocol: Ultra-Low Dose Nivolumab for Advanced Solid Tumors
Ultra-low-dose nivolumab significantly improved overall survival compared to chemotherapy in patients with relapsed refractory solid tumors while reducing severe toxicities. The re
New Reference: Nivolumab for Advanced Gastric/Esophageal AdenoCa
Nivolumab combined with chemotherapy continues to show superior overall survival and progression-free survival compared to chemotherapy alone at 5 years in advanced gastroesophagea
New Reference: Camrelizumab with Chemotherapy for Advanced Nasopharyngeal Carcinoma
The addition of camrelizumab to chemotherapy provided significant improvement in overall survival in patients with recurrent or metastatic nasopharyngeal carcinoma. The trial demon
New Drug: Anbenitamab for HER2-Positive Gastric Cancer
The study illustrates that anbenitamab plus chemotherapy significantly improves progression-free survival and overall survival in patients with HER2-positive gastric cancer who hav
New Protocol: Venetoclax with Dexamethasone for Rel/Ref Myeloma with t(11;14)
In the CANOVA study, venetoclax-dexamethasone did not significantly improve progression-free survival compared to pomalidomide-dexamethasone in patients with t(11;14)-positive rela
New Protocol: Tucatinib with Trastuzumab and Pertuzumab for Maintenance in HER2-Positive Breast Cancer
The study found that adding tucatinib to trastuzumab and pertuzumab significantly improved progression-free survival compared with placebo, with a hazard ratio of 0.641. Tucatinib
New Protocol: Tiragolumab and Atezolizumab with Chemotherapy in 1st Line Advanced Esophageal SCC
This phase 3 trial demonstrated that the combination of tiragolumab and atezolizumab with chemotherapy significantly improved progression-free and overall survival compared to chem
New Protocol: Talquetamab + Teclistamab for Extramedullary Myeloma
Talquetamab plus teclistamab achieved a high response rate of 79% in patients with drug-resistant, true extramedullary myeloma. Median progression-free survival was 15.4 months and
